Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.33 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.33 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18520396 | 0.86 | ALDH1A1 (0.41) | ALDH1A1ALOX15TSHRKDM4EMEN1 | |
| SCHEMBL2072565 | 0.80 | ALDH1A1 (0.47) | ALDH1A1ALOX15TSHRKDM4EMEN1 | |
| SCHEMBL9830230 | 0.79 | KMT2A (0.37) | ALDH1A1KDM4EMEN1KMT2AL3MBTL1 | |
| SCHEMBL9178364 | 0.79 | KDM4E (0.40) | ALDH1A1KDM4EMEN1KMT2AL3MBTL1 | |
| SCHEMBL6474069 | 0.79 | CDK1 (0.35) | ALDH1A1ALOX15TSHRKDM4EMEN1 | |
| SCHEMBL3444583 | 0.72 | ALDH1A1 (0.39) | ALDH1A1ALOX15TSHRKDM4EMEN1 | |
| SCHEMBL1703281 | 0.72 | LMNA (0.45) | ALDH1A1ALOX15TSHRKDM4EMEN1 | |
| SCHEMBL801870 | 0.72 | ALDH1A1 (0.39) | ALDH1A1ALOX15TSHRMEN1KMT2A | |
| SCHEMBL23234853 | 0.72 | KDM4E (0.33) | ALDH1A1KDM4ELMNAGLAHPGD | |
| SCHEMBL22716008 | 0.70 | ALDH1A1 (0.41) | ALDH1A1TSHRKDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12384790-B2 | Pteridinone compounds and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-08-12 | — | — | US | disclosed |
| WO-2025056065-A1 | CHEMOKINE RECEPTOR ANTAGONIST, PHARMACEUTICAL COMPOSITION, AND USE | 上海医药集团股份有限公司 | 2025-03-20 | — | — | WO | disclosed |
| CN-119638669-A | Chemokine receptor antagonist, pharmaceutical composition and application | 上海医药集团股份有限公司 | 2025-03-18 | — | — | CN | disclosed |
| CN-118946360-A | Bicyclic heteroarenes and methods of use thereof | 奇尼塔公司 | 2024-11-12 | — | — | CN | disclosed |
| EP-4444317-A2 | BICYCLIC HETEROARENES AND METHODS OF THEIR USE | Kineta, Inc. (US) | 2024-10-16 | — | — | EP | disclosed |
| US-12083121-B2 | Substituted piperazines as KRAS G12C inhibitors | AMGEN INC. (US) | 2024-09-10 | — | — | US | disclosed |
| WO-2024146541-A1 | MACROCYCLIC COMPOUNDS AS USP1 INHIBITORS | GUANGDONG NEWOPP BIOPHARMACEUTICALS CO., LTD. (CN) | 2024-07-11 | — | — | WO | disclosed |
| WO-2024123968-A1 | RNA TARGETING COMPOUNDS AND USES THEREOF | RANAR THERAPEUTICS, INC. (US) | 2024-06-13 | — | — | WO | disclosed |
| WO-2024123968-A1 | RNA TARGETING COMPOUNDS AND USES THEREOF | RANAR THERAPEUTICS, INC. (US) | 2024-06-13 | — | — | WO | disclosed |
| CN-112218865-B | Pteridinone compounds and uses thereof | 沃泰克斯药物股份有限公司 | 2024-03-12 | — | — | CN | disclosed |
| US-8288371-B2 | Ortho pyrrolidine, benzyl-substituted heterocycle CCR1 antagonists for autoimmune diseases and inflammation | PHARMACOPEIA, LLC (US) | 2012-10-16 | — | — | US | disclosed |
| US-20120220575-A1 | N-SUBSTITUTED OXAZINOPTERIDINES AND OXAZINOPTERIDINONES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-08-30 | — | — | US | disclosed |
| US-20120220575-A1 | N-SUBSTITUTED OXAZINOPTERIDINES AND OXAZINOPTERIDINONES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-08-30 | — | — | US | disclosed |
| US-20120220575-A1 | N-SUBSTITUTED OXAZINOPTERIDINES AND OXAZINOPTERIDINONES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-08-30 | — | — | US | disclosed |
| EP-2100894-A1 | Pyridopyrimidines used as Plk1 (polo-like kinase) inhibitors | 4SC AG (DE) | 2009-09-16 | — | — | EP | disclosed |
| WO-2009082526-A2 | ORTHO PYRROLIDINE, BENZYL-SUBSTITUTED HETEROCYCLE CCR1 ANTAGONISTS FOR AUTOIMMUNE DISEASES & INFLAMMATION | PHARMACOPEIA, INC. (US) | 2009-07-02 | — | — | WO | disclosed |
| WO-2009082526-A2 | ORTHO PYRROLIDINE, BENZYL-SUBSTITUTED HETEROCYCLE CCR1 ANTAGONISTS FOR AUTOIMMUNE DISEASES & INFLAMMATION | PHARMACOPEIA, INC. (US) | 2009-07-02 | — | — | WO | disclosed |
| US-20090093472-A1 | ORTHO PYRROLIDINE, BENZYL-SUBSTITUTED HETEROCYCLE CCR1 ANTAGONISTS FOR AUTOIMMUNE DISEASES & INFLAMMATION | PHARMACOPEIA, INC. (US) | 2009-04-09 | — | — | US | disclosed |
| US-20090093472-A1 | ORTHO PYRROLIDINE, BENZYL-SUBSTITUTED HETEROCYCLE CCR1 ANTAGONISTS FOR AUTOIMMUNE DISEASES & INFLAMMATION | PHARMACOPEIA, INC. (US) | 2009-04-09 | — | — | US | disclosed |
| US-20090093472-A1 | ORTHO PYRROLIDINE, BENZYL-SUBSTITUTED HETEROCYCLE CCR1 ANTAGONISTS FOR AUTOIMMUNE DISEASES & INFLAMMATION | PHARMACOPEIA, INC. (US) | 2009-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093472-A1 | ORTHO PYRROLIDINE, BENZYL-SUBSTITUTED HETEROCYCLE CCR1 ANTAGONISTS FOR AUTOIMMUNE DISEASES & INFLAMMATION | CCR1, CCR4, CCR3 | ALDH1A1 931/4885ALOX15 1204/4885TSHR 1685/4885 |
| US-20120220575-A1 | N-SUBSTITUTED OXAZINOPTERIDINES AND OXAZINOPTERIDINONES | PIK3CD, PIK3CA, AKT2 | ALDH1A1 895/4885ALOX15 610/4885TSHR 3199/4885 |
| US-12083121-B2 | Substituted piperazines as KRAS G12C inhibitors | KRAS, NRAS, HRAS | ALDH1A1 3126/4885ALOX15 3098/4885TSHR 4241/4885 |
| US-12384790-B2 | Pteridinone compounds and uses thereof | DPYD, PKD1, TYMP | ALDH1A1 569/4885ALOX15 1639/4885TSHR 3747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.